Crossmark

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status

Published Online: 2022-05-24

Published Print: 2022-07

Authors

Huang, Qing

Deering, Kathleen L. https://orcid.org/0000-0003-1438-444X
Harshaw, Qing

Leslie, Lori A.
Funding

Funding for this research was provided by:

Janssen Pharmaceuticals
License Information

Text and Data Mining valid from 2022-05-24

Version of Record valid from 2022-05-24
More Information

Article History

Received: 3 August 2021

Accepted: 9 November 2021

First Online: 24 May 2022

Document is current